Evidence map›Paper›PMID 28376179›Full record

ArticleJournal of the National Cancer Institute2017

Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.

Xifeng Wu, Yuanqing Ye, Carlos H Barcenas, Wong-Ho Chow, Qing H Meng, Mariana Chavez-MacGregor, Michelle A T Hildebrandt, Hua Zhao, Xiangjun Gu, Yang Deng and 4 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. The functional TNF-αBreast cancer research and treatment · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Development of Predictive Models for Survival among Women with Breast Cancer in Malaysia.International journal of environmental research and public health · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Xifeng WuDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuanqing YeDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos H BarcenasBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wong-Ho ChowDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qing H MengLaboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mariana Chavez-MacGregorBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle A T HildebrandtDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hua ZhaoDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiangjun GuDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang DengDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth WagarLaboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francisco J EstevaPerlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Debu TripathyBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gabriel N HortobagyiBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
NCI NIH HHS K12 CA088084
6 · The paper itself

Abstract

Background: In this study, we developed integrative, personalized prognostic models for breast cancer recurrence and overall survival (OS) that consider receptor subtypes, epidemiological data, quality of life (QoL), and treatment. Methods: A total of 15 314 women with stage I to III invasive primary breast cancer treated at The University of Texas MD Anderson Cancer Center between 1997 and 2012 were used to generate prognostic models by Cox regression analysis in a two-stage study. Model performance was assessed by calculating the area under the curve (AUC) and calibration analysis and compared with Nottingham Prognostic Index (NPI) and PREDICT. Results: Host characteristics were assessed for 10 809 women as the discovery population (median follow-up = 6.09 years, 1144 recurrence and 1627 deaths) and 4505 women as the validation population (median follow-up = 7.95 years, 684 recurrence and 1095 deaths). In addition to the known clinical/pathological variables, the model for recurrence included alcohol consumption while the model for OS included smoking status and physical component summary score. The AUCs for recurrence and OS were 0.813 and 0.810 in the discovery and 0.807 and 0.803 in the validation, respectively, compared with AUCs of 0.761 and 0.753 in discovery and 0.777 and 0.751 in validation for NPI. Our model further showed better calibration compared with PREDICT. We also developed race-specific and receptor subtype-specific models with comparable AUCs. Racial disparity was evident in the distributions of many risk factors and clinical presentation of the disease. Conclusions: Our integrative prognostic models for breast cancer exhibit high discriminatory accuracy and excellent calibration and are the first to incorporate receptor subtype and epidemiological and QoL data.

Indexed as

Models, TheoreticalNeoplasm Recurrence, LocalAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedOutcome Assessment, Health CarePrecision MedicinePrognosisProportional Hazards ModelsQuality of LifeBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID28376179
PMCPMC6279311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.